Drugs / Tasquinimod
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04405167 | Jul 2020 → May 2025 | plasma cell myeloma | University of Pennsylvania | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02396368 | Mar 2015 → Jul 2017 | prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1 | NCT01513733 | Jan 2012 → Jun 2015 | prostate cancer | Andrew J. Armstrong, MD | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06605586 | Feb 2025 → Dec 2027 expected | myelofibrosis | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06327100 | Aug 2024 → May 2029 expected | myelofibrosis, primary myelofibrosis | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT02159950 | Jan → Jul 2015 | hormone-resistant prostate carcinoma, metastatic prostate carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01732549 | Jan 2013 → Feb 2015 | castration-resistant prostate carcinoma | Ipsen | Terminated | Met primary |
| Phase 2 | NCT01743469 | Dec 2012 → Dec 2014 | gastric carcinoma, hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma | Ipsen | Completed | Missed primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT02057666 | Jan 2014 → May 2015 | castration-resistant prostate carcinoma | Ipsen | Terminated | Met primary |
| Phase 3 | NCT01234311 | Mar 2011 → Feb 2015 | prostate cancer | Active Biotech AB | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tasquinimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02057666 ↗ |
| Action | Inhibit | “Tasquinimod may stop the growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor growth.” NCT02159950 ↗ |
| Modality | Small molecule | “Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment.” PMID 28798986 ↗ Oct 2017 |
| Route | Oral | “administrated orally (capsule)” NCT01234311 ↗ |
| Target | S100A9 | “Tasquinimod, a small molecule inhibitor of S100A9” PMID 36650020 ↗ Jan 2023 |